Conceived to control
Cholesterol
LIPROSS 20
Rosuvastatin 20mg Tablet
Enabling more patients to achieve
NCEP ATP III LDL-C goals
Rosuvastation Demonstrates
• 54% relative risk reduction in myocardial infarction
• 48% relative risk reduction in stroke
• 47% relative risk reduction in revascularization procedures
In Primary Prevention of CVD
Slowing the Progression of Atherosclerosis
Dyslipidemia